GLAXOSMITHKLINE SPON ADR(CNV 2 ORD GBP0.25) (GSK)
48,60 USD ISIN US37733W1053
-2,96% | -1,48
25/07/2014 22:02
GLAXOSMITHKLINE (GSK)
1.433,00 GBp ISIN GB0009252882
+0,70% | +10,00
28/07/2014 10:23
July 27, 2014, 6:30 p.m. EDT
Glaxo CEO floats possible consumer spin-off: report
By Michael Kitchen
LOS ANGELES (MarketWatch) -- GlaxoSmithKline PLC's UK:GSK +0.70% GSK -2.96% chief executive said the British drug giant was open to spinning off its consumer health-care business at some point in the future, according to comments in a Financial Times interview published Sunday. Glaxo CEO Andrew Witty said there were no immediate plans for such a break-up, however, and voiced optimistism about turning the company around, citing a $20 billion consumer-health-care joint venture with Novartis AGCH:NOVN -0.31% NVS -0.81% , the FT reported. Glaxo is currently struggling with a variety of challenges, including a bribery scandal in China, and last week the pharmaceutical major issued a profit warning.
Aucun commentaire:
Enregistrer un commentaire